TL-925

N/A

Report date: 2024/03/14 11:21:47
NMEFirst In Class

Base Information

Drug NameTL-925
Drug Alias NameTL-925
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsDry Eye SyndromesConjunctivitis, Allergic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaIND
Originator CompaniesTelios Pharmaceuticals
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTelios PharmaceuticalsCutia Therapeutics (Wuxi) Co Ltd
Inactive CompaniesN/A
Active IndicationsDry Eye SyndromesConjunctivitis, Allergic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A